RAAS could be involved in the COVID‐19 pathogenesis and could balance the RAAS by increasing ACE2 or blocking the interaction between AngII, and AT1/AT2 could be a potential therapeutic target for COVID‐19.44 Here, ACE2 is linked to COVID-19.